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Abstract
Mutant forms of the Plasmodium falciparum transporter PfCRT constitute the key determinant of parasite resistance to
chloroquine (CQ), the former first-line antimalarial, and are ubiquitous to infections that fail CQ treatment. However,
treatment can often be successful in individuals harboring mutant pfcrt alleles, raising questions about the role of host
immunity or pharmacokinetics vs. the parasite genetic background in contributing to treatment outcomes. To examine
whether the parasite genetic background dictates the degree of mutant pfcrt-mediated CQ resistance, we replaced the wild
type pfcrt allele in three CQ-sensitive strains with mutant pfcrt of the 7G8 allelic type prevalent in South America, the
Oceanic region and India. Recombinant clones exhibited strain-dependent CQ responses that ranged from high-level
resistance to an incremental shift that did not meet CQ resistance criteria. Nonetheless, even in the most susceptible clones,
7G8 mutant pfcrt enabled parasites to tolerate CQ pressure and recrudesce in vitro after treatment with high concentrations
of CQ. 7G8 mutant pfcrt was found to significantly impact parasite responses to other antimalarials used in artemisinin-
based combination therapies, in a strain-dependent manner. We also report clinical isolates from French Guiana that harbor
mutant pfcrt, identical or related to the 7G8 haplotype, and manifest a CQ tolerance phenotype. One isolate, H209, harbored
a novel PfCRT C350R mutation and demonstrated reduced quinine and artemisinin susceptibility. Our data: 1) suggest that
high-level CQR is a complex biological process dependent on the presence of mutant pfcrt; 2) implicate a role for variant
pfcrt alleles in modulating parasite susceptibility to other clinically important antimalarials; and 3) uncover the existence of a
phenotype of CQ tolerance in some strains harboring mutant pfcrt.
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Introduction
The massive use of chloroquine (CQ) in the 20
th century
heralded substantial gains in the global fight against malaria.
These advances were later lost as CQ resistance (CQR) arose and
spread throughout malaria-endemic areas [1,2]. Today, CQ and
the alternative first-line antimalarial sulfadoxine-pyrimethamine
have officially been mostly replaced by artemisinin-based combi-
nation therapies (ACTs) [3]. Nevertheless, CQ continues to be
widely used in parts of sub-Saharan Africa at the household level,
presumably because of its ability to provide temporary relief from
symptoms for patients unable to afford ACTs or other expensive
drugs [4,5]. Recent findings also suggest the possibility of
reintroducing CQ-based combination therapies into African
regions where an extended hiatus from CQ use has led to the
dominance of CQ-sensitive Plasmodium falciparum parasites that
have outcompeted the less-fit CQ-resistant strains [6]. At the
cellular level, CQ is thought to act by accumulating to low
millimolar concentrations in the acidic digestive vacuole of asexual
intra-erythrocytic Plasmodium parasites, wherein it interferes with
the detoxification of iron-bound heme moieties produced as a
result of hemoglobin degradation [7].
Clinical and epidemiological studies reveal that CQR emerged
on very few occasions despite its abundant use, leading researchers
to initially posit a multigenic basis of resistance [8]. This theory
was challenged by the finding that CQR was inherited as a single
locus in a genetic cross between the CQ-resistant Dd2 (Indochina)
and the CQ-sensitive HB3 (Honduras) clones [9,10]. The causal
determinant in this locus was ultimately identified as the P.
falciparum chloroquine resistance transporter (pfcrt), whose 49 kDa
protein product PfCRT resides on the DV membrane [11,12].
Comparison of the Dd2 and HB3 sequence revealed eight point
mutations that all mapped to sites within or near several of the 10
putative transmembrane domains [11].
Quantitative trait loci analysis of the HB36Dd2 cross has
revealed that mutant pfcrt from the Dd2 parent accounts for .95%
of the CQ response variation among the progeny [13]. Further
evidence supporting pfcrt as the primary determinant of CQR has
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extensive linkage disequilibrium surrounding the pfcrt locus in CQ-
resistant isolates [14]. These data suggest that strong selective
sweeps drove mutant pfcrt through P. falciparum populations across
the globe, a notion also supported by more recent studies of
nucleotide diversity in geographically distinct strains [15,16]. The
PfCRT K76T mutation, ubiquitous to CQ-resistant strains, has
proven to be a highly sensitive marker of CQR in vitro and is
associated with a significantly increased risk of CQ treatment
failure in vivo [17–19].
While these studies have demonstrated the primary importance
of pfcrt in CQR, other evidence suggests that additional genes
might contribute to the CQR phenotype. Most notably, a strain-
dependent association has been demonstrated between mutant
pfcrt and point mutations in pfmdr1. This may reflect parasite
physiologic adaptations to counteract the fitness cost of mutant
PfCRT, or an independent role for pfmdr1 in CQR [1,8,19–22].
Nevertheless, even with identical pfcrt and pfmdr1 alleles, large
variations in response to CQ can exist, suggestive of a secondary
effect of additional parasite factors [13,23–25].
Clinically, resistance to CQ is graded by the World Health
Organization ETF-LTF-ACPR system (corresponding to early
treatment failure, late treatment failure, or adequate clinical and
parasitological response), based on the time to manifest clinical or
parasitological evidence of treatment failure [26]. Studies aimed at
dissecting the roles of pfcrt and pfmdr1 mutations in modulating the
different grades of in vivo resistance have shown an increased risk of
early treatment failure with PfCRT K76T, which in some reports
is augmented with PfMDR1 N86Y [27,28]. However, the PfCRT
K76T molecular marker cannot reliably predict CQ treatment
failure, revealing moderate specificity of this marker. Discordance
between in vitro parasite responses and in vivo patient outcomes
following CQ treatment can be as high as 20% [17,29]. This
discordance can be partially attributed to host and environmental
factors, including patient immunity, individual pharmacokinetic
differences, polyclonal infections, and limitations in obtaining
repeated measurements of drug susceptibilities with patient isolates
[30]. An additional explanation could be the variable presence of
additional parasite determinants.
We have previously adopted allelic exchange strategies to show
that different mutant pfcrt alleles could confer verapamil (VP)-
reversible CQR in a single, defined genetic background, the CQ-
sensitive strain GC03 [31]. A separate transfection-based study
found that pfcrt-mediated CQR in two geographically distinct
strains, Dd2 (from Indochina) and 7G8 (from Brazil), was entirely
dependent on the presence of the K76T mutation [32]. These
strains were chosen as they encode a PfCRT haplotype frequently
observed in Africa and Asia (Dd2) or in Papua New Guinea, South
America and India (7G8). Both alleles have been documented in
multiple clinical trials to be highly specific for CQ treatment
failures, with repeated evidence of significant selection for mutant
pfcrt of either allelic type in early or late treatment failures.
Frequencies of mutant alleles in those cases often attained 100%
[17,33–37]. Trials were conducted in Africa, Southeast Asia,
South America or the Oceanic region.
Here, we have assessed the effect of mutant pfcrt on the CQ
response of three CQ-sensitive strains. We also describe two isolates
from French Guiana that provide clinical validation of our genetic
investigations. Our data reveal the existence of a mutant PfCRT-
mediated CQ tolerance phenotype in some strains of P. falciparum.
Results
Generation of recombinant lines expressing mutant pfcrt
To define the impact of mutant pfcrt on CQ response in diverse
genetic backgrounds, we developed an allelic exchange strategy
based on a single round of homologous recombination and single-
site crossover integration (Figure 1A), and applied this to the CQ-
sensitive P. falciparum strains 3D7 (isolated in the Netherlands),
D10 (Papua New Guinea), and GC03 (a progeny of the
HB36Dd2 genetic cross). This strategy differed from an earlier
approach that required two rounds of allelic exchange to generate
the desired recombinants [31]. Briefly, we constructed selectable
transfection plasmids that contained a 2.9 kb pfcrt insert consisting
of 0.5 kb of the endogenous 59 untranslated region (UTR), exon 1,
intron 1, and the remaining exons 2–13 (Figure 1A). This
truncated 59 UTR fragment (termed D59) was previously observed
by luciferase assays to give insignificant levels of activity (A. Sidhu,
unpublished data). Single-site crossover between the pfcrt insert
and the homologous pfcrt sequence upstream of codons 72–76 was
predicted to replace the endogenous pfcrt gene with a recombinant
allele harboring all the single nucleotide polymorphisms from the
7G8 or Dd2 pfcrt allele. Expression of this recombinant allele was
driven by the endogenous full-length (3.0 kb) 59 UTR and a
previously characterized, functional 0.7 kb 39 UTR (termed Py39)
from the pfcrt ortholog in Plasmodium yoelii [31]. In addition to these
pBSD-7G8 and pBSD-Dd2 constructs, we also generated the
control pBSD-GC03 plasmid that encoded the wild type (WT) pfcrt
sequence in order to obtain recombinant control parasites.
3D7, D10 and GC03 parasites were transfected with the pBSD-
7G8, pBSD-Dd2, or pBSD-GC03 plasmids and screened monthly
by PCR for homologous recombination at the pfcrt locus. With the
7G8 and GC03 alleles, integration into the pfcrt locus was first
detected within 60 days of electroporation, and subsequently
cloned by limiting dilution. In contrast, the Dd2 allele failed to
show PCR evidence of homologous recombination even after 200
days of continuous culture in 3 separate transfection experiments,
suggesting that this allele was detrimental to the growth of 3D7
and D10 parasites (data not shown). Repeated efforts failed to
transfect 7G8 and Dd2 pfcrt alleles into the CQ-sensitive strains
MAD1 and Santa Lucia (from Madagascar and Santa Lucia, a
Author Summary
Plasmodium falciparum resistance to the antimalarial drug
chloroquine has been found to result primarily from point
mutations in PfCRT, which provide a highly sensitive
marker of in vivo treatment failure and in vitro resistance.
Debate has nonetheless continued about the singular role
of mutant PfCRT and the contribution of the parasite
genetic background. To address this, we have generated
recombinant P. falciparum lines expressing a mutant pfcrt
allele, or the reference wild type allele, in three distinct
chloroquine-sensitive strains. Their analysis reveals a
spectrum of responses ranging from high-level resistance
to a previously unrecognized tolerance phenotype. The
latter is characterized by virtually unchanged chloroquine
IC50 values, significantly elevated IC90 values, and the
ability to recrudesce after exposure to drug concentrations
that are lethal to chloroquine-sensitive parasites. This
tolerance phenotype was also observed in an isolate from
French Guiana, confirming its presence in malaria-endemic
regions. Mutant PfCRT significantly affected parasite
responses to other antimalarials, including ones used in
artemisinin-based combination therapies, in a strain-
dependent manner. Our data suggest that successful CQ
treatment of drug-resistant parasites is dependent on both
host immunity and the strain-dependent extent to which
mutant pfcrt imparts resistance.
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respectively), as well as HB3. Recombinant parasites either never
appeared following plasmid electroporation and drug selection, or
the plasmids never integrated into the pfcrt locus.
Successful transfection of the 3D7, D10 and GC03 strains
produced the recombinant mutant clones 3D7
7G8-1, 3D7
7G8-2,
D10
7G8-1, D10
7G8-2, GC03
7G8-1 and GC03
7G8-2 (all generated
from the plasmid containing the 7G8 pfcrt sequence) or the
Figure 1. pfcrt allelic exchange strategy and molecular characterization of clones. (A) Schematic representation of single-site crossover
between the transfection plasmid pBSD-7G8 and the endogenous pfcrt allele, leading to expression of a recombinant allele containing the 7G8
polymorphisms (black circles), transcribed from the endogenous 3.0 kb full-length promoter. In some parasites the downstream plasmid sequence
integrated as tandem linear copies (delineated as square brackets with a copy number n$0). The distal truncated locus harbored the D59 UTR, which
was previously found in luciferase assays to have minimal activity. E, EcoRI; B, BglII. (B) Southern blot hybridization of EcoRI/BglII–digested genomic
DNA samples hybridized with a pfcrt probe from the 59 UTR and exon 1 region (depicted in panel A). (C) PCR analyses of the recombinant clones and
parental lines. (D) Transcript levels from the functional and truncated pfcrt loci (terminated by Py39 and Pf39 UTRs respectively in the case of the
recombinant clones). Data are presented as a percentage of total pfcrt transcript levels normalized against the respective WT control (3D7 or D10). (E)
Western blot analysis of recombinant and parental lines, probed with antibodies to PfCRT or the ER-Golgi marker PfERD2 [80]. (F) Signals were
quantified, normalized against PfERD2, and expressed as a proportion of the signals obtained in the appropriate parental line. (B–F) Lanes: 1-3D7, 2-
3D7
C, 3-3D7
7G8-1, 4-3D7
7G8-2, 5-D10, 6-D10
C, 7-D10
7G8-1, and 8-D10
7G8-2. GC03 clones were also confirmed by PCR, sequencing, and Southern
hybridization, and were found to have similar levels of pfcrt RNA and protein expression as compared with the 3D7 and D10 clones (data not shown).
doi:10.1371/journal.ppat.1000887.g001
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c, D10
c and GC03
c clones
(generated with the control plasmid harboring the WT pfcrt
sequence; Table 1). Southern hybridization of EcoRI/BglII-
digested genomic DNA samples with a pfcrt probe confirmed the
expected recombinant locus, as evidenced by the loss of a 3.9 kb
band present in the WT lines and the acquisition of 4.4 kb and
6.7 kb bands consistent with recombination in pfcrt (results shown
for the 3D7 and D10 clones in Figure 1B). The 7.2 kb bands
present in 3D7
C, D10
7G8-1, and D10
7G8-2 were indicative of
integration of tandem plasmid copies into the pfcrt locus.
We confirmed these recombination events using PCR analyses
with a 59 UTR-specific primer (p1) and an exon 5-specific primer
(p2), which revealed a change in size from the 1.8 kb WT-specific
band to a shorter 1.5 kb band in the recombinant controls and
mutants reflecting the loss of introns 2–4 (Figure 1C). The
recombinant controls and mutants also showed the acquisition of
PCR bands specific for the full-length functional copy of the pfcrt
locus (2.2 kb, p1+p3) and the downstream truncated copy (1.1 kb,
p4+p5) (Figure 1C). Sequencing of these PCR products (data not
shown) confirmed that the integration event placed the K76T
mutation in the functional locus, and that the WT allele was
displaced to the downstream non-functional locus. Reverse-
transcriptase (RT)-PCR assays on synchronized ring stage RNA
with primers specific to exons 2 and 5 (p6+p2) produced a single
band corresponding to cDNA, with no evidence of genomic DNA
contamination (data not shown). Sequence analysis of those
products detected transcripts only from the functional recombi-
nant locus (under the control of the 3.0 kb full-length 59 UTR) and
not from the downstream truncated locus (data not shown). No
endogenous WT locus was detected in any recombinant clone.
To precisely assess the transcriptional status of the functional vs.
the truncated pfcrt copies, we performed quantitative real-time
RT-PCR utilizing primers specific for transcripts containing the
Py39 vs. Pf39 UTRs respectively. Quantification of pfcrt steady state
transcript levels was made by extrapolation from a standard curve
generated from genomic DNA of D10
C, which has a single copy of
the pBSD-GC03 plasmid integrated into the pfcrt locus (Figure 1B).
Results showed that transcription from the functional pfcrt allele
with Py39 accounted for 93–95% of the total pfcrt transcript within
each line (Figure 1D). Western blot analysis showed that PfCRT
protein levels in the recombinant 3D7 and D10 lines were 55–66%
and 45–63% those observed in the parental controls respectively
(Figures 1E and 1F). This finding of reduced pfcrt transcript and
protein expression levels following allelic exchange is consistent
with earlier pfcrt transfection studies [31,32,38]. Importantly, those
studies have shown that reduced pfcrt expression in recombinant
lines causes a concomitant reduction in CQ IC50 values, which
thus become lower than the IC50 values observed in parasites
harboring non-recombinant pfcrt. In our drug assays, the IC50
value refers to the drug concentration that inhibits incorporation
of [
3H]-hypoxanthine, a marker of in vitro parasite growth, by
50%.
Mutant pfcrt is insufficient to confer high-level
chloroquine resistance in the 3D7 and D10 genetic
backgrounds
Once the desired integration events were confirmed, we assessed
the effect of mutant pfcrt on the CQ response in the recombinant
lines. In the 3D7 background, mutant pfcrt was found to confer a
2.7-fold increase in CQ IC50 values (mean6SEM CQ IC50 values
of 84614 nM and 79611 nM for 3D7
7G8-1 and 3D7
7G8-2
respectively) compared to the 3D7 recombinant control
(2962 nM, P,0.001; Figure 2A, Table S1). These values were
2.4-fold lower than the IC50 values for WT 7G8 (190614 nM).
For the D10 mutants, there was no significant increase in CQ IC50
values for D10
7G8-1 and D10
7G8-2 compared to D10
C (63611 nM,
71616 nM, and 4563 nM, respectively, P.0.05).
Table 1. Summary of pfcrt-modified lines and reference strains.
PfCRT haplotype (72–371)
PfMDR1 haplotype (86–
1246) Microsatellite marker
Line Parent
Transfection
Plasmid 72 74 75 76 220 271 326 350 356 371 86 184 1034 1042 1246
pfmdr1
copy
number TA81 TA87 ARA2 PfPK2
3D7 C M N K A Q N C I R N Y S N D 1 173 82 102 170
3D7
c 3D7 pBSD-GC03 C M N K A Q N C I R N Y S N D 1 173 82 102 170
3D7
7G8-1,2 3D7 pBSD-7G8 S MNTSQ D C L R N Y S N D 1 173 82 102 170
D10 C M N K A Q N C I R N Y S N D 1 170 82 102 164
D10
c D10 pBSD-GC03 C M N K A Q N C I R N Y S N D 1 170 82 102 164
D10
7G8-1,2 D10 pBSD-7G8 S MNTSQ D C L R N Y S N D 1 170 82 102 164
G C 0 3 CM NKAQ N CI R N YS D D 1 182 95 102 161
GC03
c GC03 pBSD-GC03 C M N K A Q N C I R N Y S D D 1 182 95 102 161
GC03
7G8-1,2 GC03 pBSD-7G8 S MNTSQ D C L RNY SD D 1 182 95 102 161
7G8 S MNTSQ D C L RNFC D Y 1 170 98 98 173
G224 S MNTSQ D C L RNF S DY1 170 98 98 173
H209 S MNTSQ DR L RNF S DY1 176 98 98 173
H B 3 C M N K A QNC I RNY SD D 1 182 92 102 193
Dd2 C IE T S E S C TI Y Y S N D 4 176 95 108 161
Transfection plasmids encoding for the chloroquine (CQ)-sensitive GC03 allele or the CQ-resistant 7G8 allele were transfected into CQ-sensitive parental strains 3D7, D10 and
GC03 to generate the recombinant control and mutant lines. PfCRT and PfMDR1 haplotypes are shown for the polymorphic amino acid residues. Residues that differ from the
wild-type sequence are shown in bold. pfmdr1 copy number was determined by quantitative PCR. Results of genotyping with microsatellite markers are shown for each line.
doi:10.1371/journal.ppat.1000887.t001
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desethyl-chloroquine (mdCQ), a significant decrease in suscepti-
bility was found in both genetic backgrounds. The 3D7 mutant
clones demonstrated a 10-fold increase in mdCQ IC50 values
compared to 3D7
C (P,0.001, Figure 2B). In comparison, the IC50
values for the D10
7G8-1 mutant were 5-fold higher than D10
C
(P,0.01, Figure 2B, D10
7G8-2 was not tested). Nevertheless, the
mdCQ IC50 values in both backgrounds were approximately 2–
fold lower than those observed in WT 7G8, suggesting that mutant
pfcrt was insufficient to confer high-level mdCQ resistance to 3D7
and D10 parasites.
These findings of a relatively moderate, strain-dependent
decrease in CQ susceptibility in the 3D7 and D10 pfcrt mutants
contrasted with our earlier observation that the introduction of 7G8
mutant pfcrt in the GC03 background resulted in CQ IC50 values
.100 nM [31]. To directly compare the effects of mutant pfcrt
between strains, and to assess for any potentially confounding
differences in our transfection strategies, we generated recombinant
control (GC03
C) and mutant clones expressing the 7G8 allele
(GC03
7G8-1 and GC03
7G8-2) using our single-round transfection
strategy. These clones were confirmed by PCR, sequencing, and
Southernhybridization,and werefoundtohavesimilarlevelsofpfcrt
RNA and protein expression compared to the 3D7 and D10 clones
(data not shown).In the GC03 background, introductionof the 7G8
mutant pfcrt allele increased the CQ IC50 values 4.7-fold (P,0.001),
from 2763 nM for GC03
C to ,13068 nM for both recombinant
clones (Figure 2A, Table S1), and increased the mdCQ IC50 values
by 9-fold (P,0.01; Figure 2B). These determinations included four
independent assays that directly compared GC03
7G8-1 and
GC03
7G8-2 with the C6
7G8 line. The latter was produced using
our earlier pfcrt modification strategy involving consecutive rounds
of allelic exchange [31]. C6
7G8 also expresses the 7G8 pfcrt allele in
the GC03 background, yet differs from the clones produced in the
current study in that C6
7G8 contains both the human dihydrofolate
reductase and the bsd selectable markers, and lacks the 0.5 kb
59UTR present in the downstream pfcrt loci in the GC03
7G8-1 and
GC03
7G8-2 clones (see Figure 1A). Drug assays with these lines
produced CQ IC50 values of 13167, 12968 and 13067 nM for
GC03
7G8-1, GC03
7G8 and C6
7G8 respectively (Table S1). These
results are comparable to our published data with C6
7G8
(127617 nM; [31]) and are consistent with both allelic exchange
strategies producing the same CQ responses. Our data from all
three strains also provide clear evidence that the degree of CQR
conferred by mutant pfcrt is strain-dependent.
We also found that the genetic background influenced the
degree of VP chemosensitization, a hallmark of P. falciparum CQR
Figure 2. In vitro response of pfcrt-modified clones to chloroquine and its primary metabolite monodesethylchloroquine. In vitro [
3H]-
hypoxanthine incorporation assays were performed with the WT, control, and mutant pfcrt clones. All lines were tested in duplicate against CQ6VP
and mdCQ6VP an average of 7 times (range 4–11; see summary in Table S1). Mean6SEM IC50 values are presented for (A) CQ and (B) its metabolite
mdCQ. Statistical comparisons comparing mutant pfcrt-modified lines against recombinant control lines of the same genetic backgrounds were
performed using one-way ANOVA with a Bonferroni post-hoc test. **P,0.01; ***P,0.001. (C–E) Percent inhibition of growth (shown as means6SEMs
derived from all assays) across a range of CQ concentrations for (C) 3D7, (D) D10, and (E) GC03 lines.
doi:10.1371/journal.ppat.1000887.g002
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VP reversibility of 2461% and 2861% (calculated as the
mean6SEM of percent reversibility for all CQ and mdCQ
values), compared to 4462% for GC03 (Figure S1). Notably,
significant VP reversibility occurred in the D10 mutants despite
the lack of a significant increase in CQ IC50 values (Figure 2D,
Table S1). By comparison, VP reversibility for 7G8 CQ and
mdCQ responses was 4663% (Figure 2B). This is lower than the
degree of VP reversibility that results from expression of the Dd2
pfcrt allele [31,40].
Analysis of the dose response curves generated during these
studies revealed a more complex picture than was evident from the
IC50 values alone. For all three genetic backgrounds, introduction
of the 7G8 mutant allele into the CQ-sensitive strains caused a
pronounced change in the slope of the dose-response profiles, with
evidence of continued growth at high CQ concentrations
(Figures 2C–E). This was particularly pronounced for the
recombinant D10
7G8-1 and D10
7G8-2 lines, whose CQ IC50 values
were similar to those of D10 and D10
C, yet whose IC90 values (i.e.
the drug concentrations that inhibited [
3H]-hypoxanthine uptake
into cultured parasites by 90%) were greatly elevated. Indeed,
analysis of the CQ IC90/IC50 ratios for the lines in each genetic
background revealed significant increases in the mean ratios of the
mutant lines (Figure S2). For the 3D7 and D10 backgrounds in
particular, the relatively modest increase in CQ IC50 values
appeared to be compensated by an increased ability of these
parasites to withstand high CQ concentrations.
The genetic background dictates whether mutant pfcrt
confers chloroquine resistance or tolerance
We posited that these elevated IC90 values imparted by mutant
pfcrt subtly reflected a CQ tolerance phenotype. To test this, we
assayed our lines for the ability to survive treatment with 50 nM
CQ, a concentration that was lethal after three generations of
exposure for all three WT strains, and 80 nM CQ, which
substantially exceeded each of their CQ IC90 values (Table S1).
Parental, control, and mutant lines were assayed for in vitro
recrudescence (defined as 50% of cultures testing positive for
growth) after a six-day exposure to CQ. The parental and
recombinant control lines from the 3D7, D10, and GC03
backgrounds showed no signs of growth at 30 days post-exposure
to 50 nM CQ (Figures 3A and 3B). In contrast, 3D7
7G8-1
recrudesced at 9 and 13 days post-treatment with 50 nM and
80 nM CQ respectively (Figure 2A). We also tested 3D7
7G8-1 that
had been pretreated with 50 nM CQ for 3 generations
approximately 30 days earlier (3D7
7G8-1/preCQ), and observed
similar rates of recrudescence. All untreated lines were positive at
day 7, as was WT 7G8 that showed no inhibition of growth with
80 nM CQ treatment.
Although the introduction of mutant pfcrt resulted in no
significant increase in CQ IC50 values in the D10 background,
both D10
7G8-1 and pretreated D10
7G8-1/preCQ recrudesced at
days 13 and 17 with treatment with 50 nM and 80 nM CQ,
respectively (Figure 3B). In the GC03 background, GC03
7G8-1
showed no inhibition of growth at 7 days with both 50 nM and
Figure 3. CQ recrudescence data for pfcrt -modified and parental clones. Lines were subjected to 50 nM or 80 nM CQ for 6 days and assayed
for recrudescence every 2–3 days from days 7–30. Pooled data from two independent experiments were plotted as the percent of positive wells as a
function of time post-CQ exposure. The panels show (A) 3D7 and (B) D10 clones and controls, including recombinant clones pretreated with 50 or
80 nM CQ. All no-treatment controls were positive on day 7 (as shown for 7G8+80 nM CQ), as was GC03
7G8-1 treated with both 50 nM and 80 nM CQ.
doi:10.1371/journal.ppat.1000887.g003
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imparted by mutant pfcrt in this strain.
Characterization of chloroquine-sensitive P. falciparum
clinical isolates from French Guiana that possess mutant
pfcrt
Given the evidence that mutant pfcrt was insufficient to confer
CQR in all genetic backgrounds, we asked whether there were
CQ-sensitive parasites harboring mutant pfcrt in the field. After an
extensive search, this led to the identification of two clinical
isolates from French Guiana that express the PfCRT K76T
marker for CQR but are sensitive to CQ. These isolates, G224
and H209, were harvested in 2003 and 2004, respectively, and
were genotyped at the pfcrt and pfmdr1 loci. The PfCRT
haplotype of G224 was found to be identical to that of 7G8,
whereas H209 possessed a C350R mutation that has not been
previously described (Table 1). Both G224 and H209 possessed a
single copy of pfmdr1 with the same haplotype that differed from
7G8 only at position 1034. Western blot analyses revealed
equivalent levels of PfCRT expression compared to 7G8 (data not
shown).
Drug susceptibility assays using CQ and mdCQ showed that
these strains had low IC50 values for CQ (mean IC50 values of
5268 nM and 3567 nM for G224 and H209, respectively) and
mdCQ (mean IC50 values of 349646 nM and 7069 nM)
(Figures 4A and 4B, Table S1). Further, both G224 and H209
demonstrated VP reversibility of their CQ and mdCQ response
(averaging 37% and 35%, respectively; Table S1, Figure S1).
Analysis of the CQ inhibition curves revealed that the IC90 values
were skewed towards the IC90 of 7G8 (Figure 4C), reminiscent of
the effect seen in our 3D7 and D10 mutant pfcrt lines (Figures 2C
and 2D). This was particularly pronounced for G224, whose IC90
for CQ was 123627 nM. When tested for in vitro recrudescence
after a 6-day exposure to CQ, G224 recrudesced at days 11 and 17
when treated with 50 nM and 80 nM CQ respectively (Figure 3D).
Interestingly, H209 showed recrudescence at days 21 and 25 for
50 nM and 80 nM CQ respectively, despite having a very low CQ
IC90 value of 4467 nM.
The genetic background also determines the effect of
mutant pfcrt on response to other antimalarials
To test whether the host strain also influenced the effect of
mutant pfcrt on parasite response to other drugs, particularly those
currently used in ACTs, we tested our lines against quinine (QN),
artemisinin (ART), monodesethyl-amodiaquine (mdADQ, the
potent in vivo metabolite of amodiaquine), lumefantrine (LMF),
and piperaquine (PIP). The responses of the French Guiana
isolates G224 and H209 were also assessed.
In the 3D7, D10 and GC03 backgrounds, we observed no
effect of mutant pfcrt on QN response (Figure 5A, Table S1).
Interestingly, the highest QN IC50 values were observed with
H209, which showed a moderately high level of resistance
(405640 nM). When tested against ART, introduction of mutant
pfcrt showed a significant 2–fold decrease in IC50 values in the
D10 and GC03 backgrounds, when compared to recombinant
clones expressing WT pfcrt (P,0.05 and P,0.01 respectively;
Figure 5B). 3D7
7G8-1 also yielded a 33% lower ART IC50
compared to the 3D7
C control, however this did not attain
statistical significance (P=0.06). Again, the highest ART IC50
values were observed with H209 (Table S1). For mdADQ,
3D7
7G8-1 had a 1.5-fold increase in IC50 value compared to 3D7
C
(P,0.05), and GC03
7G8-1 showed an even more pronounced
Figure 4. Characterization of the French Guiana isolates G224 and H209. (A–B) In vitro [
3H]-hypoxanthine incorporation assays against
CQ6VP (A) and mdCQ6VP (B) were performed with a CQ-sensitive (3D7) and a CQ-resistant (Dd2) control line. All lines were tested in duplicate on
average 6 times (range 3–8). Mean6SEM IC50 values were derived by linear extrapolation. (C) Percent inhibition of growth (means6SEM derived from
all assays) determined across a range of CQ concentrations. (D) Lines were exposed to 50 nM or 80 nM CQ for 6 days and assayed for recrudescence
every 2–3 days from days 7–30. All no-treatment controls were positive on day 7 (as shown for 7G8+80 nM CQ).
doi:10.1371/journal.ppat.1000887.g004
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C (P,0.01; Figure 5C).
There was no effect of mutant pfcrt on mdADQ response in the
D10 background. With this drug, G224 and H209 were both
moderately resistant, as was 7G8.
Introduction of mutant pfcrt was also found to confer
significantly increased sensitivity to LMF in all three strains,
equating to a 23%, 44%, and 35% decrease in IC50 values for
the 3D7, D10, and GC03 backgrounds respectively (Figure 5D).
H209 was also found to be less susceptible to LMF than was
G 2 2 4 ,m i r r o r i n gt h e i rr e s p o n s e st oQ Na n dA R T .F i n a l l y ,w e
found that mutant pfcrt had a significant effect on PIP response
only in the D10 background, in which D10
7G8-1 was 1.7-fold
less sensitive than D10
C (P,0.05). G224 and H209 were found
to be 2.7- and 1.7-fold more sensitive to PIP when compared to
7G8.
Discussion
Here, we provide evidence that the genetic background of P.
falciparum determines whether expression of mutant pfcrt allele
confers a full CQR phenotype, as defined by CQ IC50 values that
exceed the in vitro CQR threshold [30], or instead mediates
increased tolerance to CQ, as evidenced by dose-response shifts
manifesting primarily at the IC90 level. All our recombinant clones
expressing mutant pfcrt recrudesced in vitro after being exposed for
three generations to concentrations of CQ that were uniformly
lethal to CQ-sensitive parasites; however the rate of recrudescence
varied with the genetic background. The GC03 mutant lines,
which had the highest CQ IC50 values, showed no growth
inhibition. In contrast, the pfcrt-mutant lines generated in the 3D7
and D10 backgrounds, as well as the clinical isolates G224 and
Figure 5. In vitro response of pfcrt-modified clones and French Guiana isolates to clinically important antimalarials. In vitro [
3H]-
hypoxanthine incorporation assays were performed in duplicate an average of 6 separate times (range 3–12 independent assays). Mean6SEM IC50
values are presented for (A) quinine (QN), (B) artemisinin (ART), (C) monodesethyl-amodiaquine (mdADQ), (D) lumefantrine (LMF), and (E) piperaquine
(PIP). Statistical comparisons comparing mutant pfcrt-modified lines against recombinant control lines of the same genetic backgrounds were
performed using unpaired student t tests. *P,0.05; **P,0.01. For brevity, a single recombinant mutant clone is presented for each host strain.
Results from additional recombinant mutant lines are included in Table S1.
doi:10.1371/journal.ppat.1000887.g005
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parasites.
Based on our findings, we propose that IC50 values, which
typically constitute the sole measurement of CQ response in vitro,
adequately identify high-level CQR but are insufficient to detect
strains that have low-level resistance or manifest tolerance to CQ.
Instead, our data suggest that accurate determinations of IC90
values provide a more predictive measure of whether parasites can
recrudesce in the presence of CQ concentrations that are lethal to
drug-sensitive parasites, a trait that we here refer to as CQ
tolerance. Tolerance is also apparent in decreased parasite
susceptibility to the primary drug metabolite mdCQ. We posit
that pfcrt-mediated CQ tolerance might be an important
component of late treatment failures in patients. These are
classified as cases where symptoms occur during a follow-up period
of 4–28 days post CQ treatment, or asymptomatic infection
appearing 7–28 days post-treatment (see the WHO 2006
publication on malaria treatment: http://whqlibdoc.who.int/
publications/2006/9241546948_eng_full.pdf). In contrast, early
treatment failures might result more often from infections with
parasites in which mutant pfcrt exerts a higher degree of CQR.
Early treatment failures are classified as the development of
clinical or parasitological symptoms during the first three days
following CQ treatment. We note that clinically, care must be
taken when evaluating early failures, as these can also include
patients that respond relatively slowly to treatment yet progress to
full cure. Moreover, the joint effects of low-level CQ resistance
reported here and acquired protective immunity might help
explain why CQ treatment can successfully cure some infections
harboring mutant pfcrt parasites in semi-immune individuals
[1,18]. The importance of immunity in shaping the host’s ability
to resolve drug-resistant infections harboring mutant pfcrt was first
demonstrated in work from Mali that found that successful CQ
treatment of pfcrt mutant parasites was strongly dependent on age,
a known surrogate for protective immunity in endemic areas [18].
These data complement other observations in the malaria
literature indicating that the immune response can allow a
relatively ineffective drug to clear an infection, and even at times
clear infections without therapy [41,42]. Our data extend these
reports by suggesting that successful CQ treatment of drug-
resistant parasites is dependent both on the level of host immunity
and the strain-dependent extent to which mutant pfcrt imparts
CQR.
A review of our CQ IC50 data reveals a relatively weak effect of
mutant pfcrt, which attained the widely used in vitro CQR threshold
of 80–100 nM only for GC03 (Figure 2, Table S1). This threshold,
however, was based on studies with field isolates [30] and does not
readily extrapolate to our pfcrt-modified parasite lines. Our data
(Figure 1) show that these lines underexpress pfcrt, a consequence
of allelic exchange into this locus that was earlier shown to cause
artificially low CQ IC50 values whose level of reduction was
concordant with the degree of reduced expression [31,32,38]. In
our current study, the importance is not the absolute levels of
CQR that we measured, but rather the finding that the genetic
background of CQ-sensitive strains dictates a spectrum of mutant
pfcrt-mediated changes in CQ response that ranges from tolerance
to high-level resistance.
We note that our data were obtained with the 7G8 pfcrt allele,
which is known to have appeared independently in South America
and the Oceanic region in or near Papua New Guinea and has
recently spread throughout India [43]. The 7G8 haplotype
(C72S/K76T/A220S/N326D/I356L) shares only two mutations
(K76T/A220S) with the Dd2 haplotype (I74E/N75E/K76T/
A220S/Q271E/N326S/I356T/R371I) that is common to Africa
and SE Asia [11,14,44]. Our earlier allelic exchange studies on
recombinant lines generated in the GC03 strain found that the
7G8 pfcrt haplotype confers a lower degree of resistance than that
imparted by the Dd2 allele (averaging 15% and 45% less or CQ
and mdCQ respectively). This was consistent with the intrinsic
differences observed between the parental 7G8 and Dd2 strains
[31]. It is possible that in the D10 and 3D7 strains, higher degrees
of resistance might have been observed with the Dd2 allele,
however we were unable to test this. We note that D10 originates
from Papua New Guinea where the 7G8 allele is highly prevalent,
and our lack of success with introducing the Dd2 pfcrt allele into
either this strain or 3D7 suggests a physiologic context that
precludes expression and normal viability. Other evidence of a
fitness cost imparted by the Dd2 allele comes from studies in
Malawi showing that this allele is progressively lost from the
parasite population in the absence of sustained CQ pressure
[45,46].
Field studies have sometimes reported discordance in the
association of K76T and in vitro CQR, suggesting the contribution
of other genetic loci [24,47–49]. However, the interpretation of
these results has been confounded by potential inaccuracies
stemming from measuring one-time drug responses from fre-
quently polyclonal fresh patient isolates. Our study provides, to the
best of our knowledge, the first report of culture-adapted,
monoclonal isolates that harbor mutant pfcrt and that, based on
multiple drug susceptibility assays, show low CQ IC50 values that
fail to meet the standard criteria for CQR. These findings,
obtained with the G224 and H209 isolates from French Guiana,
therefore provide indisputable evidence that mutant pfcrt is
insufficient to confer CQR to all genetic backgrounds. Neverthe-
less, both isolates exhibited tolerance to high CQ concentrations
and recrudesced under CQ pressure. Microsatellite typing
revealed a close genetic similarity between G224 and 7G8
(Table 1), with the exception of the residue at PfMDR1 position
1034 that could potentially affect CQ response [22,50].
Of particular interest, H209 was highly sensitive to CQ and yet
demonstrated delayed recrudescence (Figure 4). This might in part
be attributable to the PfCRT C350R charge substitution in
transmembrane domain 9, a region postulated to function in
substrate binding and translocation [51]. Studies are underway to
introduce the H209 pfcrt allele, encoding the C350R mutation,
into GC03 parasites to compare these to the GC03
7G8 parasites
whose expressed pfcrt allele differs only at codon 350 (Table 1). We
note that an adjacent charge substitution at residue 352 (Q352K/
R) was previously selected by QN pressure in a CQ-resistant line,
with a concomitant reversion to CQ-sensitivity [52]. The H209
line also showed elevated IC50 values for QN, as well as ART,
when compared to G224 and 7G8 (Figure 4). Of note, QN-
doxycycline, and more recently artemether-LMF, have been
implemented as first line antimalarials in French Guiana since the
cessation of CQ use for the treatment of P. falciparum malaria in the
mid 1990s [53]. Indeed, a recent report from French Guiana
documented the existence of several field isolates with elevated
artemether IC50 values (.30 nM in 7 of 289 isolates), suggesting
decreased susceptibility to this agent [54]. G224 was tested at that
time and found to have an artemether IC50 value of ,1 nM.
H209, which yielded artemisinin IC50 values two-fold higher than
G224 (Table S1), was isolated one year later. Our subsequent
studies reveal comparable IC50 values between these two lines with
the more potent clinical derivatives artemether, artesunate and
artemether (values provided in Table S1).
ACTs are rapidly assuming the role of first line antimalarials
around the world [55]. Our studies with isogenic pfcrt-modified
lines confirm previous reports that mutations in PfCRT can
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larials that constitute these ACTs [19,56], and provide evidence
that for certain drugs this effect is strain-dependent (Figure 5). In
the case of the fast-acting ART, all three strains displayed
enhanced susceptibility upon introduction of mutant pfcrt. With the
amodiaquine metabolite mdADQ, elevated IC50 values were
noted in two of the three recipient strains, supporting earlier
epidemiological evidence that mutant PfCRT might contribute to
a multigenic basis of amodiaquine resistance ([57–59]; see below).
The opposite effect was observed with the bisquinoline PIP, which
is highly effective against CQ-resistant strains of P. falciparum [60],
and for which we observed a strain-dependent increase in
susceptibility. For LMF, significantly enhanced susceptibility was
observed in all three genetic backgrounds, supporting recent field
studies [59,61]. The generally enhanced potency of LMF and
artemisinin derivatives against mutant pfcrt parasites bodes well for
the widely used LMF-artemether co-formulation. The enhanced
susceptibility conferred by the mutant pfcrt 7G8 allele to the ACT
partner drugs LMF and PIP, but not amodiaquine, has potentially
important implications in regional antimalarial drug policy.
Our pfcrt and CQ data speak to a requirement for additional
parasite factors that, at least in some strains, either augment the
level of PfCRT-mediated CQR or on the contrary, create an
intracellular physiologic environment in which PfCRT is unable to
exert its full capacity to dictate CQR [62,63]. pfmdr1 would appear
to be one gene that contributes to this strain-dependent effect.
Transfection-based studies have shown that in CQ-resistant strains
that harbor mutant pfcrt, mutations in pfmdr1 can contribute to
elevated CQ IC50 values, but only in a subset of strains. Mutant
pfdmr1 alone shows no effect on CQ response in sensitive parasites
harboring wild-type pfcrt [19,20]. Evidence from CQ treatment
trials in African, Southeast Asia and the Oceanic region show that
mutant pfmdr1 is associated with an increased risk of CQ treatment
failure, however this risk is usually substantially higher in the
presence of mutant pfcrt [17,28,36,64,65]. Of note, while mutant
pfcrt is virtually ubiquitous to CQ treatment failures, mutant pfmdr1
is often absent ([65] and references therein). Functional assays
have yet to be developed to test whether pfmdr1 can directly reduce
drug toxicity, or instead is associated with CQR because of its non-
random association with mutant pfcrt, which potentially could
relate to improved parasite fitness [66].
We note that in our study, pfmdr1 cannot account for differences
in the extent to which mutant pfcrt affects CQ response, as both the
resistant 3D7 and the tolerant D10 mutants (3D7
7G8 and D10
7G8
respectively) share the same wild-type pmfdr1 haplotype (Table 1).
The highly resistant GC03 mutants (GC03
7G8) differ in having the
pfmdr1 N1042D mutation that in allelic exchange studies had no
impact on CQ response (although it did affect a number of other
antimalarials including QN, mefloquine and ART; [21]). Clear
evidence that mutant forms of PfCRT and PfMDR1 can combine
in a region-specific manner to create higher levels of drug
resistance comes from the recent study by Sa et al. [67], showing
that the 7G8 South American haplotypes of these two determi-
nants produce high-level resistance to mdADQ. This study also
found that the Asian/African Dd2 haplotype of PfCRT was
associated with high level CQR with minimal apparent contribu-
tion from variant PfMDR1 haplotypes.
Why has no gene other than pfmdr1 been found associated with
CQR? In the case of the HB36Dd2 genetic cross where mutant
pfcrt was clearly the primary determinant, evidence that modula-
tory factors must exist was provided by the 2.7-fold spread in CQ
IC50 values observed among the CQ-resistant progeny [13]. Such
factors may be present within the 36 kb CQR-associated linkage
group harboring pfcrt [10,68], or potentially might already be
present in the HB3 parent, thereby rendering this competent for
CQR and masking the inheritance of a secondary determinant [8].
To test the latter hypothesis, we attempted to introduce mutant
pfcrt into the HB3 strain, but were unable to obtain integrants in
three independent transfection experiments (data not shown).
Independent genomic approaches analyzing linkage disequilibri-
um in CQ-resistant isolates have also failed to identify any gene
besides pfcrt [14–16,69], as elaborated upon below.
The genetic identity of these secondary determinants associated
with CQR may reflect the geographic distribution of distinct
PfCRT haplotypes around the globe [19]. Indeed, the PfCRT
7G8 haplotype found in South America and the Pacific is typically
associated with PfMDR1 N1042D/D1246Y (6S1034C), whereas
the PfCRT Dd2 haplotype common to Asia and Africa is often
associated in CQ-resistant isolates with PfMDR1 N86Y [43,50].
Identifying additional genetic determinants has been complicated
by the complexity of performing genome-wide association studies
with large numbers of culture-adapted parasite lines from different
geographic regions and comparing these to parasite drug responses
[50,70]. Major advances have recently been achieved in a seminal
study by Mu et al. [69], who performed genome-wide association
studies with a 3,000 single nucleotide diversity array probed with
DNA from189 culture-adapted P. falciparum lines from Africa,
Asia, Papua New Guinea and South America, and compared their
genetic diversity with CQ response. When accounting for local
population structures, the authors found associations between CQ
response and changes in pfcrt, pfmdr1, and surprisingly a putative
tyrosine kinase (PF11_0079). These associations could only readily
be discerned in African populations where a sufficient number of
CQ-sensitive strains could be identified; as opposed to South
American, Asian and Papua New Guinean strains where mutant
pfcrt remained at a high prevalence. Of the genes listed above, pfcrt
stood out as being one of handful of genes in the parasite genome
that were apparently under very substantial selection pressure in
all three populations studied - Asia, Africa and South America. No
other genes were convincingly associated with CQR, even though
a number of genes potentially involved in drug transport (including
the putative drug/metabolite transporter PF14_0260, and the
ABC transporters PF13_0271 and PFA0590w) were found to be
under lesser selection pressure in local populations. We note that
evidence of selection was also observed in genes adjacent to pfcrt,
although these may simply represent genetic hitchhiking and
insufficient time for genetic recombination to have disrupted these
associations.
Our conclusion from these studies is that mutant pfcrt has been
the dominant genetic force that has driven CQR across the globe,
with some degree of participation from mutant pfmdr1, and that
even the phenotype of CQ tolerance observed herein in D10
parasites expressing mutant pfcrt would appear sufficient to confer
substantial levels of viability during a course of CQ treatment.
This level of protection against drug onslaught, while appearing
modest in vitro, appears to have sufficed for selection and rapid
mobility through parasite populations subjected to CQ treatment.
Experiments to define secondary determinants that can augment
CQR would require, as an example, deeper sequence coverage of
the set of 189 genotypically and phenotypically characterized
isolates mentioned above [69], followed by quantitative trait loci
analysis that computationally subtracted the dominant effect of
pfcrt to identify potential residual associations in local parasite
population structures.
Other hypothesis-driven approaches to identify secondary
parasite factors could involve investigations into the function of
mutant PfCRT and the cellular basis of CQ mode of action.
Recent studies based on heterologous expression of codon-
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have recently provided compelling evidence that mutant PfCRT
can transport CQ [71], a finding consistent with earlier evidence
from Pichia pastoris and Dictyostelium discoideum [72,73]. The Xenopus
study also identified peptides that could interfere with transport of
radiolabeled CQ through mutant PfCRT, raising the possibility
that PfCRT is involved in transport of certain peptide sequences
out of the DV and into the cytoplasm ([74] and references therein).
Secondary factors could potentially alter the kinetics of peptide
production (resulting from hemoglobin proteolysis in the DV) or
their translocation into the parasite cytosol and subsequent
conversion into amino acids that can be incorporated into newly
synthesized proteins.
Other potential factors could relate to the tri-peptide glutathi-
one (GSH) and redox regulation. Interestingly, an earlier study by
Ginsburg and colleagues reported that altering the intracellular
levels of GSH caused a corresponding shift in CQ susceptibility in
P. falciparum [75]. Work from these authors led to the hypothesis
that GSH could degrade iron-bound heme (a toxic byproduct of
hemoglobin degradation) that might be released into the parasite
cytosol as a result of CQ action [76]. Further support for a
relationship between GSH and levels of CQR was recently
obtained following the genetic disruption of the P. falciparum gene
PfMRP (PFA0590w), whose ABC transporter product has been
localized to the parasite surface. These knockout parasites,
generated in the CQ-resistant W2 strain, accumulated more
radioactive GSH and CQ and became less resistant to CQ as well
as several other antimalarials [77]. Indirect additional evidence of
a potential link between CQR and GSH comes from the recent
report that PfCRT homologs in Arabidopsis thaliana can mediate
GSH transport when assayed in Xenopus oocytes [78]. Collectively,
these data suggest that GSH homeostasis is related to CQR, and
possibly to PfCRT, in a strain-dependent manner. A multifacto-
rial, and potentially region-specific basis for these differences
would have precluded their identification to date. Further
investigations into parasite cell biology, employing genomic,
proteomic and metabolomic studies to compare CQ response
phenotypes within regional populations, are warranted to identify
these molecules and their determinants. French Guinea may well
provide an ideal set of geographically restricted isolates in which to
define these factors, because of its complex history of antimalarial
drug usage and the existence of mutant pfcrt strains with both
resistance and tolerance phenotypes.
Materials and Methods
Ethics statement
Informed consent was not required for this study as the collection
of samples from malaria patients for drug susceptibility testing are
part of the French national recommendations for the care and
surveillance of malaria. As the Pasteur Institute French Guiana
laboratory is the regional malaria reference center, blood samples
are sent to the laboratory by practitioners (from health centers,
private medical offices and hospitals) for drug susceptibility testing,
as part of the national regular medical surveillance. This included in
vitro drug susceptibility testing and assessments of molecular
markers. This research is mandated by the French Ministry of
Health, and has been approved by the Institutional Review Boards
of the Pasteur Institute in Paris and in French Guiana.
Plasmid constructs
pfcrt plasmid inserts were assembled from two contiguous
sequences. The first 800 bp sequence, spanning 0.5 kb of the pfcrt
59 UTR (denoted D59) through to the intron 1/exon 2 junction
(nucleotides 22960–23747 of the GenBank accession number
AF030694), was amplified from Dd2 genomic DNA with the
primers p251 and 10AE1-39A (a list of these and all other primers
used in this study is provided in Table S2). A 2.1 kb fragment
corresponding to pfcrt exons 2–13 and the 39 UTR of the P. yoelii
ortholog pycrt (termed Py39) was released following AvrII/BamHI
digestion of the plasmids pBSD/AE123 -7G8, -GC03, and -SC01
(the latter has the Dd2 sequence) [31]). These two sequences were
assembled in pCR2.1 (Invitrogen) to generate a 2.9 kb pfcrt
fragment containing D59, exon 1, intron 1, exons 2–13, and Py39.
This insert was subcloned as a SacII/BamHI fragment into the
pCAM-BSD transfection plasmid. This plasmid expresses the bsd
selectable marker, which is under control of a 0.6 kb P. falciparum
calmodulin (cam)5 9 UTR and a 0.6 kb P. falciparum hrp2 39 UTR.
The resulting 7.2 kb plasmids were designated pBSD-7G8, pBSD-
GC03, and pBSD-Dd2.
Parasite transfections and DNA analysis
The P. falciparum 3D7, D10, and GC03 strains were cultured in
human erythrocytes, transfected as described [21], and selected
with 2.0 mg/ml blasticidin HCl (Invitrogen). Upon integration,
recombinant parasites were cloned by limiting dilution and
identified using Malstat assays [31]. The isolates from French
Guyana were collected from malaria patients referred to the
reference malaria laboratory of the Pasteur Institute of Guyana, in
Cayenne, France. Each year this work was reviewed and approved
by the Pasteur Institute Surveillance Committees of Guyana and
Paris. The institutional review board of the Columbia University
Medical Center also reviewed and approved the P. falciparum
culture work.
PCR-based detection of plasmid integration into transfected
parasites (Figure 1) used the pfcrt 59 UTR-specific primer p1, the
pfcrt exon 5-specific primer p2, the Py39-specifc primer p3, the pfcrt
intron 2-specific primer p4, and the plasmid-specific primer p5.
For Southern blot analysis, 1 mg of DNA was digested with EcoRI/
BglII, electrophoresed, and transferred onto nylon membranes.
Hybridizations were performed with a hexamer-primed [
32P]-
labeled probe prepared from the 0.8 kb fragment spanning D59,
exon1 and intron 1, and released following SacII/AvrII digestion of
the transfection plasmid pBSD-Dd2. The full-length sequence of
pfcrt was determined from the complete coding sequence amplified
from cDNA using the primers p251+BB116C and sequenced
internally with the primers CF5C, BB84, AF12, AB22, AB25, and
BB116B. For sequencing of the upstream pfmdr1 polymorphic
residues at positions 86 and 184, genomic DNA was amplified with
the primers p423+p231, and the resulting 0.7 kb products were
sequenced with p231. For the downstream polymorphic residues
at positions 1034, 1042, and 1246, the 0.8 kb amplification
product of p426+p215 was sequenced with p238. pfmdr1 copy
number was measured by Taqman quantitative real-time PCR
and quantified with the DDCt method as described elsewhere [79].
Genomic DNA samples were run twice in triplicate.
Quantitative real-time RT-PCR assays
The expression of pfcrt in the recombinant clones was assessed by
quantitative real-time PCR assays performed with the QuantiTect
SYBR Green PCR Kit (Qiagen) on an Opticon2 (BioRad).
Expression from the different alleles (endogenous and genetically
introduced) was analyzed utilizing primers specific for the two
different39UTRs,designated Py39andPf39.Fortheloci containing
Py39, the primers p1752 and p1753 were used to generate a 182 bp
amplicon. For the locus containing Pf39, a 191 bp amplicon was
generated using the primers p1754 and p1756. PCR conditions
were optimized so that the relative efficiencies of the Pf39 and Py39
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volumes with 300 nM of each primer, 3 mM Mg
2+, and 1/80
th of
theoligo(dT)primedcDNA generatedfrom 1.5 mg oftotalRNA.As
a control for each sample, a 150 bp amplicon of b-actin was
amplified using the primers A129 and A130, using the same
conditions as for Py39 and Pf39 except that the Mg
2+ concentration
was 3.5 mM. All amplifications were performed with 15 minutes of
hot start at 95uC, followed by 40 cycles of denaturing for 30 seconds
at 95uC, annealing for 30 seconds at 49uC, and extension for 30
seconds at 62uC. Melting curve analysis was performed for each
assay to verify that a single melting peak was produced, indicating a
single specific PCR product for each reaction. A standard curve for
each reaction was generated with 10-fold serial dilutions of genomic
DNA, spanning the range of 5 to 5610
5 genome copies). This
genomic DNA was prepared from D10
C, a recombinant clone
shown by Southern hybridizationto havea single copy of eachlocus
(Py39 and Pf39, Figure 1B). Each sample was run in triplicate on
three separate occasions.
Protein analysis
Protein extracts were prepared from sorbitol-synchronized
trophozoite-stage parasites. For each sample, protein from
,1610
6 parasites was loaded per well, electrophoresed on 12%
SDS-PAGE gels, and transferred onto polyvinylidene difluoride
membranes. Membranes were probed with rabbit anti-PfCRT
antibodies (diluted 1:2,500) [11], followed by incubation with
horseradish peroxidase-conjugated donkey anti-rabbit IgG
(1:10,000; Amersham Biosciences). Rabbit anti-PfERD2 antibod-
ies (diluted 1:1,000) [80] were used as an independent loading
control. Bands were visualized by enhanced chemiluminescence
(Amersham Biosciences) and quantified by densitometric analysis
of autoradiograph data using NIH ImageJ 1.386(http://rsb.info.
nih.gov/ij). PfCRT band intensities were normalized against the
PfERD2 bands to correct for minor differences in protein loading.
In vitro antimalarial drug assays
Parasite susceptibilities to antimalarial drugs were measured in
vitro by [
3H]-hypoxanthine incorporation assays, as described [81].
Briefly, predominately ring-stage cultures were seeded in duplicate
in 96-well plates at 0.4% parasitemia and 1.6% hematocrit.
Parasites were exposed to a range of drug concentrations, or no
drug controls, for 72 hr, with 0.5 mCi per well of [
3H]-
hypoxanthine added at the 48 hr time point. IC50 and IC90
values were extrapolated by linear regression, as described [81].
Compounds were tested in duplicate on 4–11 separate occasions
for CQ and mdCQ and 3–12 separate occasions for the other
drugs. In some assays, VP was included at 0.8 mM final
concentration. Statistical analyses comparing mutant pfcrt-modi-
fied lines against recombinant control lines of the same genetic
backgrounds were performed using one-way ANOVA with a
Bonferroni post-hoc test for CQ and mdCQ, or unpaired student t
tests for quinine (QN), artemisinin (ART), monodesethyl-amodi-
aquine (mdADQ), lumefantrine (LMF), and piperaquine (PIP).
In vitro recrudescence assays
Parasites were assayed for their ability to grow under short-term
exposure to high CQ concentrations. Predominately ring-stage
cultures were seeded in 96-well plates at 0.2% parasitemia and
1.6% hematocrit. Parasites were exposed for 6 days to no drug,
50 nM CQ, or 80 nM CQ, with daily media changes. Drug
pressure was then removed on day 7 and parasite growth was
measured using Malstat assays ([31]). From days 7 through 30,
media changes and Malstat assays were performed every two days,
and the cultures cut 1:2 into fresh erythrocytes weekly until the
detection of positive wells. As part of this experiment, cultures of
3D7
7G8-1 and D10
7G8-1 were exposed to 50 nM CQ for 6 days
and maintained until parasites became microscopically detectable,
at days 15 and 20 respectively. These CQ-pretreated cultures were
assayed for recrudescence alongside 7G8, 3D7
C, 3D7
7G8-1, D10
C,
D10
7G8-1, GC03
C, and GC03
7G8-1. Data were pooled from two
independent experiments in which each line was assayed in
duplicate for the no drug controls and in triplicate for the 50 nM
and 80 nM CQ treatments.
Malstat assays
These were performed as described [82], with minor modifi-
cations. Briefly, 100 mL of Malstat reagent was added to 50 mLo f
culture supernatant and incubated for 1 hr. Absorbance at
595 nM was measured on a VICTOR
3 Multilabel Plate Reader
(Perkin-Elmer). Wells positive for parasite growth were identified
based on absorbance values greater than twice those obtained
from control wells with uninfected erythrocytes. Positive wells were
verified by microscopic evaluation of Giemsa-stained thin smears.
Gene identification numbers
pfcrt: MAL7P1.27; pfmdr1: PFE1150w; pycrt: PY05061; b-actin:
PFL2215w. Pfmrp: PFA0590w. All numbers are from www.
plasmodb.org.
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